Vertex Pharmaceuticals Incorporated (0QZU.L)
USD 459.0
(-6.32%)
USD 459.0
(-6.32%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 22.73 Billion USD | 25.23% |
| 2022 | 18.15 Billion USD | 35.13% |
| 2021 | 13.43 Billion USD | 14.3% |
| 2020 | 11.75 Billion USD | 41.27% |
| 2019 | 8.31 Billion USD | 33.18% |
| 2018 | 6.24 Billion USD | 76.14% |
| 2017 | 3.54 Billion USD | 22.54% |
| 2016 | 2.89 Billion USD | 15.89% |
| 2015 | 2.49 Billion USD | 6.88% |
| 2014 | 2.33 Billion USD | 0.74% |
| 2013 | 2.31 Billion USD | -15.96% |
| 2012 | 2.75 Billion USD | 25.18% |
| 2011 | 2.2 Billion USD | 27.75% |
| 2010 | 1.72 Billion USD | -11.76% |
| 2009 | 1.95 Billion USD | 99.44% |
| 2008 | 980.47 Million USD | 63.01% |
| 2007 | 601.47 Million USD | -34.73% |
| 2006 | 921.57 Million USD | 67.87% |
| 2005 | 548.99 Million USD | 0.65% |
| 2004 | 545.45 Million USD | -24.7% |
| 2003 | 724.41 Million USD | -11.19% |
| 2002 | 815.72 Million USD | -11.83% |
| 2001 | 925.13 Million USD | 19.7% |
| 2000 | 772.88 Million USD | 232.56% |
| 1999 | 232.4 Million USD | -12.73% |
| 1998 | 266.3 Million USD | -9.91% |
| 1997 | 295.6 Million USD | 105.99% |
| 1996 | 143.5 Million USD | 44.95% |
| 1995 | 99 Million USD | -14.8% |
| 1994 | 116.2 Million USD | 90.49% |
| 1993 | 61 Million USD | 19.61% |
| 1992 | 51 Million USD | -10.68% |
| 1991 | 57.1 Million USD | 520.65% |
| 1990 | 9.2 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 23.91 Billion USD | 5.22% |
| 2024 Q2 | 20.13 Billion USD | -15.83% |
| 2024 Q3 | 22.24 Billion USD | 10.47% |
| 2023 Q1 | 18.97 Billion USD | 4.54% |
| 2023 Q3 | 21.72 Billion USD | 6.77% |
| 2023 FY | 22.73 Billion USD | 25.23% |
| 2023 Q2 | 20.34 Billion USD | 7.25% |
| 2023 Q4 | 22.73 Billion USD | 4.62% |
| 2022 FY | 18.15 Billion USD | 35.13% |
| 2022 Q2 | 15.58 Billion USD | 9.3% |
| 2022 Q3 | 16.7 Billion USD | 7.21% |
| 2022 Q4 | 18.15 Billion USD | 8.65% |
| 2022 Q1 | 14.25 Billion USD | 6.13% |
| 2021 Q2 | 12.22 Billion USD | 0.88% |
| 2021 FY | 13.43 Billion USD | 14.3% |
| 2021 Q1 | 12.11 Billion USD | 3.09% |
| 2021 Q3 | 12.61 Billion USD | 3.25% |
| 2021 Q4 | 13.43 Billion USD | 6.45% |
| 2020 Q4 | 11.75 Billion USD | 3.98% |
| 2020 Q2 | 10.21 Billion USD | 14.88% |
| 2020 Q3 | 11.3 Billion USD | 10.62% |
| 2020 FY | 11.75 Billion USD | 41.27% |
| 2020 Q1 | 8.89 Billion USD | 6.91% |
| 2019 Q1 | 6.54 Billion USD | 4.76% |
| 2019 FY | 8.31 Billion USD | 33.18% |
| 2019 Q4 | 8.31 Billion USD | 10.7% |
| 2019 Q3 | 7.51 Billion USD | 6.84% |
| 2019 Q2 | 7.03 Billion USD | 7.49% |
| 2018 Q1 | 3.95 Billion USD | 11.48% |
| 2018 Q4 | 6.24 Billion USD | 35.17% |
| 2018 Q2 | 4.33 Billion USD | 9.67% |
| 2018 Q3 | 4.62 Billion USD | 6.58% |
| 2018 FY | 6.24 Billion USD | 76.14% |
| 2017 Q2 | 3.28 Billion USD | 11.5% |
| 2017 Q4 | 3.54 Billion USD | 10.87% |
| 2017 FY | 3.54 Billion USD | 22.54% |
| 2017 Q1 | 2.94 Billion USD | 1.83% |
| 2017 Q3 | 3.19 Billion USD | -2.66% |
| 2016 FY | 2.89 Billion USD | 15.89% |
| 2016 Q3 | 2.6 Billion USD | 2.19% |
| 2016 Q4 | 2.89 Billion USD | 11.09% |
| 2016 Q2 | 2.54 Billion USD | 2.45% |
| 2016 Q1 | 2.48 Billion USD | -0.37% |
| 2015 Q3 | 2.43 Billion USD | 2.52% |
| 2015 Q1 | 2.16 Billion USD | -7.3% |
| 2015 Q2 | 2.37 Billion USD | 9.62% |
| 2015 FY | 2.49 Billion USD | 6.88% |
| 2015 Q4 | 2.49 Billion USD | 2.59% |
| 2014 Q1 | 2.19 Billion USD | -5.26% |
| 2014 Q3 | 2.4 Billion USD | 13.61% |
| 2014 FY | 2.33 Billion USD | 0.74% |
| 2014 Q4 | 2.33 Billion USD | -2.9% |
| 2014 Q2 | 2.11 Billion USD | -3.61% |
| 2013 Q4 | 2.31 Billion USD | -10.21% |
| 2013 Q3 | 2.58 Billion USD | -0.06% |
| 2013 Q2 | 2.58 Billion USD | 8.03% |
| 2013 Q1 | 2.39 Billion USD | -13.3% |
| 2013 FY | 2.31 Billion USD | -15.96% |
| 2012 Q3 | 2.71 Billion USD | 4.38% |
| 2012 FY | 2.75 Billion USD | 25.18% |
| 2012 Q1 | 2.34 Billion USD | 6.42% |
| 2012 Q4 | 2.75 Billion USD | 1.49% |
| 2012 Q2 | 2.6 Billion USD | 11.04% |
| 2011 Q2 | 1.76 Billion USD | 14.6% |
| 2011 FY | 2.2 Billion USD | 27.75% |
| 2011 Q4 | 2.2 Billion USD | 5.37% |
| 2011 Q3 | 2.09 Billion USD | 18.65% |
| 2011 Q1 | 1.53 Billion USD | -10.84% |
| 2010 Q1 | 1.77 Billion USD | -9.47% |
| 2010 FY | 1.72 Billion USD | -11.76% |
| 2010 Q4 | 1.72 Billion USD | -8.65% |
| 2010 Q3 | 1.88 Billion USD | 14.18% |
| 2010 Q2 | 1.65 Billion USD | -6.56% |
| 2009 FY | 1.95 Billion USD | 99.44% |
| 2009 Q1 | 1.56 Billion USD | 59.71% |
| 2009 Q2 | 1.43 Billion USD | -8.05% |
| 2009 Q3 | 1.57 Billion USD | 9.28% |
| 2009 Q4 | 1.95 Billion USD | 24.28% |
| 2008 Q1 | 889.5 Million USD | 47.89% |
| 2008 Q2 | 970.8 Million USD | 9.14% |
| 2008 Q3 | 1.06 Billion USD | 9.97% |
| 2008 Q4 | 980.47 Million USD | -8.16% |
| 2008 FY | 980.47 Million USD | 63.01% |
| 2007 Q1 | 835.09 Million USD | -9.38% |
| 2007 Q2 | 761.07 Million USD | -8.86% |
| 2007 FY | 601.47 Million USD | -34.73% |
| 2007 Q4 | 601.47 Million USD | -8.19% |
| 2007 Q3 | 655.14 Million USD | -13.92% |
| 2006 Q1 | 524.65 Million USD | -4.43% |
| 2006 Q4 | 921.57 Million USD | 2.16% |
| 2006 Q2 | 625.47 Million USD | 19.22% |
| 2006 Q3 | 902.11 Million USD | 44.23% |
| 2006 FY | 921.57 Million USD | 67.87% |
| 2005 Q3 | 550.57 Million USD | -7.76% |
| 2005 Q4 | 548.99 Million USD | -0.29% |
| 2005 Q1 | 484.22 Million USD | -11.22% |
| 2005 FY | 548.99 Million USD | 0.65% |
| 2005 Q2 | 596.9 Million USD | 23.27% |
| 2004 Q4 | 545.45 Million USD | -5.03% |
| 2004 Q1 | 669.18 Million USD | -7.62% |
| 2004 Q2 | 624.05 Million USD | -6.75% |
| 2004 Q3 | 574.36 Million USD | -7.96% |
| 2004 FY | 545.45 Million USD | -24.7% |
| 2003 Q1 | 840.3 Million USD | 3.01% |
| 2003 FY | 724.41 Million USD | -11.19% |
| 2003 Q3 | 742.67 Million USD | -5.69% |
| 2003 Q4 | 724.41 Million USD | -2.46% |
| 2003 Q2 | 787.45 Million USD | -6.29% |
| 2002 Q3 | 831.06 Million USD | -3.42% |
| 2002 Q4 | 815.72 Million USD | -1.85% |
| 2002 Q2 | 860.47 Million USD | -1.72% |
| 2002 Q1 | 875.51 Million USD | -5.36% |
| 2002 FY | 815.72 Million USD | -11.83% |
| 2001 Q2 | 766.83 Million USD | -0.35% |
| 2001 Q3 | 922.37 Million USD | 20.28% |
| 2001 FY | 925.13 Million USD | 19.7% |
| 2001 Q4 | 925.13 Million USD | 0.3% |
| 2001 Q1 | 769.54 Million USD | -0.43% |
| 2000 Q4 | 772.88 Million USD | -0.22% |
| 2000 Q3 | 774.56 Million USD | 80.84% |
| 2000 Q2 | 428.32 Million USD | 7.91% |
| 2000 Q1 | 396.93 Million USD | 70.8% |
| 2000 FY | 772.88 Million USD | 232.56% |
| 1999 Q1 | 249.7 Million USD | -6.23% |
| 1999 Q2 | 238.6 Million USD | -4.45% |
| 1999 Q3 | 224.8 Million USD | -5.78% |
| 1999 Q4 | 232.4 Million USD | 3.38% |
| 1999 FY | 232.4 Million USD | -12.73% |
| 1998 Q2 | 274.9 Million USD | -2.97% |
| 1998 Q1 | 283.3 Million USD | -4.16% |
| 1998 Q3 | 277.9 Million USD | 1.09% |
| 1998 Q4 | 266.3 Million USD | -4.17% |
| 1998 FY | 266.3 Million USD | -9.91% |
| 1997 Q4 | 295.6 Million USD | -1.04% |
| 1997 Q2 | 300.7 Million USD | 3.83% |
| 1997 Q1 | 289.6 Million USD | 101.81% |
| 1997 FY | 295.6 Million USD | 105.99% |
| 1997 Q3 | 298.7 Million USD | -0.67% |
| 1996 Q1 | 90.3 Million USD | -8.79% |
| 1996 FY | 143.5 Million USD | 44.95% |
| 1996 Q3 | 143.5 Million USD | 94.71% |
| 1996 Q4 | 143.5 Million USD | 0.0% |
| 1996 Q2 | 73.7 Million USD | -18.38% |
| 1995 Q2 | 106.1 Million USD | -5.1% |
| 1995 Q3 | 98.3 Million USD | -7.35% |
| 1995 Q4 | 99 Million USD | 0.71% |
| 1995 FY | 99 Million USD | -14.8% |
| 1995 Q1 | 111.8 Million USD | -3.79% |
| 1994 FY | 116.2 Million USD | 90.49% |
| 1994 Q2 | 110.4 Million USD | -3.07% |
| 1994 Q3 | 106.7 Million USD | -3.35% |
| 1994 Q1 | 113.9 Million USD | 86.72% |
| 1994 Q4 | 116.2 Million USD | 8.9% |
| 1993 Q4 | 61 Million USD | 20.08% |
| 1993 Q1 | 48.7 Million USD | -4.51% |
| 1993 Q2 | 51.6 Million USD | 5.95% |
| 1993 FY | 61 Million USD | 19.61% |
| 1993 Q3 | 50.8 Million USD | -1.55% |
| 1992 Q2 | 54.5 Million USD | -1.8% |
| 1992 FY | 51 Million USD | -10.68% |
| 1992 Q1 | 55.5 Million USD | -2.8% |
| 1992 Q3 | 52.9 Million USD | -2.94% |
| 1992 Q4 | 51 Million USD | -3.59% |
| 1991 FY | 57.1 Million USD | 520.65% |
| 1991 Q2 | 7.3 Million USD | 0.0% |
| 1991 Q3 | 32.4 Million USD | 343.84% |
| 1991 Q4 | 57.1 Million USD | 76.23% |
| 1990 FY | 9.2 Million USD | 0.0% |
| 1990 Q4 | 9.2 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -2633.017% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -2325.543% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -2822.07% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -13633.928% |
| bluebird bio, Inc. | 619.16 Million USD | -3571.129% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -17962.204% |
| Imunon, Inc. | 21.91 Million USD | -103605.304% |
| Editas Medicine, Inc. | 499.15 Million USD | -4453.754% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 14.808% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | -577.39% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -1796.238% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | -599.09% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -1513.241% |
| Verastem, Inc. | 149.71 Million USD | -15082.009% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 71.951% |
| Waters Corporation | 4.62 Billion USD | -391.267% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 76.976% |
| Biogen Inc. | 26.84 Billion USD | 15.327% |
| Nektar Therapeutics | 398.03 Million USD | -5610.632% |
| Perrigo Company plc | 10.8 Billion USD | -110.288% |
| Dynavax Technologies Corporation | 997.09 Million USD | -2179.64% |
| Illumina, Inc. | 10.11 Billion USD | -124.807% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -80297.156% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -2812.817% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -10115.545% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -34502.223% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | -232.235% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -13649.214% |
| Evolus, Inc. | 188.99 Million USD | -11926.688% |
| Adicet Bio, Inc. | 207.29 Million USD | -10865.146% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -11414.501% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 31.288% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -10945.015% |
| FibroGen, Inc. | 423.52 Million USD | -5266.858% |
| Agilent Technologies, Inc. | 10.76 Billion USD | -111.188% |
| OPKO Health, Inc. | 2.01 Billion USD | -1029.901% |
| Homology Medicines, Inc. | 47.05 Million USD | -48203.547% |
| Geron Corporation | 394.07 Million USD | -5667.974% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | -493.496% |
| Exelixis, Inc. | 2.94 Billion USD | -672.517% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -6068.471% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -14622.967% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -1647.164% |
| Zoetis Inc. | 14.28 Billion USD | -59.108% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -3764.129% |
| Abeona Therapeutics Inc. | 64 Million USD | -35414.828% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -40526.642% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -660.189% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -596.268% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -3557.213% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -1211.406% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -2066.328% |
| Insmed Incorporated | 1.32 Billion USD | -1609.247% |
| TG Therapeutics, Inc. | 329.58 Million USD | -6796.571% |
| Incyte Corporation | 6.78 Billion USD | -235.15% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -1138.771% |